Current Editions
The IRA’s boost to generics
By decreasing Medicare’s contribution to branded Part D drugs, the act can make generic drugs cheaper for plans — even after manufacturer rebates
Market Access
Product Development
Next-wave radiopharmaceuticals: insights from AACR
Fusion added to view of ɑ-emitters in lutetium-experienced patients, as Novartis, RayzeBio gave peeks at programs with broad indication potential
Regulation
FDA’s Ojemda approval marks Day One’s transition to commercial company
No black box warning and a broad label for the pediatric brain cancer therapy
Deals
AI-guided antibody designer BigHat taps J&J as latest partner as internal pipeline advances
Still years away from the clinic, the biotech now has four deals with larger pharmas that are informing decisions around its wholly-owned programs
Management Tracks
Smart to lead Actym as CEO
Plus: Ramanayake joins CureVac and updates from Oruka, Madrigal and AusBiotech
BioCentury ISSN 1097-7201